A New Medicine for Lung Injury Caused by Sulfur Mustard Exposure
A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury
This project is developing a new oral medicine, incyclinide, to help people recover from lung injuries caused by exposure to sulfur mustard.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project ID | NIH-11135448 on NIH RePORTER |
What this research studies
This research focuses on creating a new oral medication called incyclinide, which is a specially modified tetracycline, to treat lung damage from sulfur mustard exposure. Sulfur mustard is a chemical agent that can cause severe blistering and injury to the lungs, skin, and eyes. The goal is to develop a 'host-directed' treatment, meaning it works by helping your body's own defenses respond to the injury, rather than directly fighting an infection. This medicine aims to reduce the severe inflammation and tissue damage that occurs in the lungs after exposure. If successful, it could offer a vital medical countermeasure for those affected by chemical warfare or industrial accidents.
Who could benefit from this research
Good fit: Ideal candidates for future clinical applications would be individuals who have experienced lung injury due to exposure to sulfur mustard or similar vesicant agents.
Not a fit: Patients with lung injuries from causes other than sulfur mustard exposure may not receive benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this new medicine could significantly reduce lung damage and improve recovery for individuals exposed to sulfur mustard.
How similar studies have performed: Chemically modified tetracyclines have shown promise in other inflammatory conditions, and incyclinide is already in clinical stages for other uses, suggesting a foundation for this approach.
Where this research is happening
Kings Park, United States
- Cmtx Biotech, INC. — Kings Park, United States (Active)
Researchers
- Principal investigator: Veress, Livia Agnes — Cmtx Biotech, INC.
- Study coordinator: Veress, Livia Agnes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.